Acorda Therapeutics - Articles and news items

Acorda to acquire Biotie; gains rights to tozadenant

Industry news / 19 January 2016 / Victoria White

In acquiring Biotie for approximately $363 million, Acorda will obtain worldwide rights to tozadenant, an oral adenosine A2a receptor antagonist currently in Phase 3 development in Parkinson’s disease…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+